Samuel Brown
Professor · Univ of Utah Sch of Med
Credentials: · · · · · ·
History
Present
- 1997–2001
- 1993–1997
Harvard College
Research
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
New England Journal of Medicine · 2022 · 998 citations
MMWR Morbidity and Mortality Weekly Report · 2020 · 884 citations
BMJ · 2022 · 544 citations
103 papers · 2 as a fellow
75 papers
75 papers
- ML
60 papers · 4 as a fellow
59 papers
59 papers
59 papers
58 papers
Grants
- 2023–2029
The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium
National Heart, Lung, and Blood Institute · U01
Contact PI · $1.8M · Ihc Health Services, Inc.
- 2019–2025
Study of Treatment's Echocardiographic Mechanisms (CLOVERS-STEM)
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.8M · Ihc Health Services, Inc.
- 2014–2022
Long Term Outcomes and Macrophage Biology in Patients with EVALI
National Heart, Lung, and Blood Institute · U01
Contact PI · $1.3M · Ihc Health Services, Inc.
- 2014–2017
Discovery and Prediction of Novel Functional Outcome Phenotypes for ARDS
National Heart, Lung, and Blood Institute · R21
Contact PI · $216.8K · Ihc Health Services, Inc.
Clinical trials
- 2021–2022
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Principal investigator · Completed · Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
- 2021–2022
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
Principal investigator · Completed · Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)
- 2021–2022
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
Principal investigator · Completed · Phase 3
National Institute of Allergy and Infectious Diseases (NIAID)